BioCentury
ARTICLE | Company News

Arcus gets rights to PD-1 mAb from WuXi, Gloria

August 18, 2017 8:01 PM UTC

WuXi Biologics Inc. (HKSE:2269) and Harbin Gloria Pharmaceuticals Co. Ltd. (SZSE:002437) granted Arcus Biosciences (Hayward, Calif.) exclusive development and commercialization rights to PD-1 mAb GLS-010 (WBP3055). Arcus will gain rights in North America, Europe, Japan and other undisclosed regions, while Gloria will retain Chinese rights.

Under the deal, WuXi and Gloria are to receive $18.5 million up front and are eligible for up to $422.5 million in development and regulatory milestones based on the approval of 11 products that include GLS-010 as a component. WuXi and Gloria are also eligible to receive up to $375 million in commercial milestones, plus tiered single- to low double-digit royalties...